CDISC Standards Problems and Solutions: Some Examples. Paul Terrill and Sarah Brittain

Similar documents
Practical benefits of EC: building a comprehensive exposure story

Mixed Effects Models Yan Wang, Bristol-Myers Squibb, Wallingford, CT

Comparison of Mixed-Effects Model, Pattern-Mixture Model, and Selection Model in Estimating Treatment Effect Using PRO Data in Clinical Trials

BUILDING A COMPREHENSIVE. Presented dby Donald ldbenoot, SGS Life Sciences Si

PRACTICAL BENEFITS OF EC: BUILDING A COMPREHENSIVE EXPOSURE STORY. Presented by Donald Benoot, SGS Life Sciences Zegher Vereecke, SGS Life Sciences

Block Block Block

%CHCKFRQS A Macro Application for Generating Frequencies for QC and Simple Reports

Abstract REVIEW PAPER DOI: / Peter Ahnblad. International Tinnitus Journal. 2018;22(1):72-76.

Problem Points Score USE YOUR TIME WISELY USE CLOSEST DF AVAILABLE IN TABLE SHOW YOUR WORK TO RECEIVE PARTIAL CREDIT

This supplement contains the following items: 1. Original protocol, summary of changes. 2. Original statistical analysis plan

Moving on from MSTAT. March The University of Reading Statistical Services Centre Biometrics Advisory and Support Service to DFID

Author's response to reviews

21. OVERVIEW: ANCILLARY STUDY PROPOSALS, SECONDARY DATA ANALYSIS

21. OVERVIEW: ANCILLARY STUDY PROPOSALS, SECONDARY DATA ANALYSIS

E6(R2) Good Clinical Practice

Introduction to IBM SPSS Statistics (v24)

Summary of. DMC Meetings How to avoid common traps? Giacomo Mordenti Global Biometrics Head, Livanova

Tinnitus Treatment in a VA Setting

BAL Real Power Balancing Control Performance Standard Background Document

BAL Real Power Balancing Control Performance Standard Background Document

Instructions to Authors

RESEARCH INFORMATION for PEOPLE WITH APHASIA

FE REVIEW LOGIC. The AND gate. The OR gate A B AB A B A B 0 1 1

Guide to contributors. 1. Aims and Scope

ANSI/SCTE

Date Vendor name Vendor ID Website Range name Product name. Application Software Version: Firmware Revision: BACnet Protocol Revision:

Chapter 3. Allocation General

PROCESSING YOUR EEG DATA

SUMMARY OF CLINICAL EFFICACY DATA

Paired plot designs experience and recommendations for in field product evaluation at Syngenta

FOR IMMEDIATE RELEASE. Frequently Asked Questions (FAQs) The following Q&A was prepared by Posit Science. 1. What is Tinnitus?

BioGraph Infiniti Physiology Suite

Instrument Firmware Release Notes

QT Measurements on-screen Methods

Tinnitus stakeholder scoping workshop: notes from breakout group discussions Date: 31/10/17

How to write an article for a Journal? 1

Building Your DLP Strategy & Process. Whitepaper

Candidate Standard: A/107 ATSC 2.0 Standard

Software Wizard Makes Configuring the 2301E Easier Configuration Wizard Now Included in 2301E Service Tool

Evaluation of Serial Periodic, Multi-Variable Data Visualizations

REUTERS BROADCAST VIDEO 16:9 FAQS FOR PRODUCTION USERS

Australian Broadcasting Corporation Submission to the Senate Standing Committee on Environment, Communications and the Arts

Reliability. What We Will Cover. What Is It? An estimate of the consistency of a test score.

IMDB Movie Review Analysis

INSTRUCTIONS FOR AUTHORS

India Peoplemeter Update VII

ITU-T Y Specific requirements and capabilities of the Internet of things for big data

Project Reliability-based Control

JOURNAL OF PHARMACEUTICAL RESEARCH AND EDUCATION AUTHOR GUIDELINES

ITU-T Y Reference architecture for Internet of things network capability exposure

Improving Frame Based Automatic Laughter Detection

Lineside Signal Aspects and Indications

HDMI / Video Wall over IP Receiver with PoE

N12/5/MATSD/SP2/ENG/TZ0/XX. mathematical STUDIES. Wednesday 7 November 2012 (morning) 1 hour 30 minutes. instructions to candidates

Prospects for managing Sclerotinia head rot with fungicides LESSONS FROM FIELD TRIALS CONDUCTED IN 2011

Usability testing of an Electronic Programme Guide and Interactive TV applications

US FDA Enforcement in 2018 Reading the Tea Leaves

Integration of Simple LIMS with Mindray using Mirth Connect

redbox INFORMATION PACK VERSION 1.0 solutions uk

University Library Collection Development Policy

EyeFace SDK v Technical Sheet

Linear mixed models and when implied assumptions not appropriate

Master's thesis FACULTY OF SCIENCES Master of Statistics

The CYCU Chang Ching Yu Memorial Library Resource Development Policy

RSNA 2006 November 26 to December 1 Chicago. Guest author for ImPACT Dr. Koos Geleijns, Medical Physicist, Leiden University Medical Center.

Estimating. Proportions with Confidence. Chapter 10. Copyright 2006 Brooks/Cole, a division of Thomson Learning, Inc.

STREAMLINE TINNITUS TREATMENT IN YOUR BUSY PRACTICE: TINNITUS CONCERN QUESTIONNAIRE


CATHODE RAY OSCILLOSCOPE (CRO)

Endoscopy video recording guidance

STAT 113: Statistics and Society Ellen Gundlach, Purdue University. (Chapters refer to Moore and Notz, Statistics: Concepts and Controversies, 8e)

Patrick Neff. October 2017

Gamma instabus. Technical product information

Copyright 2014 ZES ZIMMER Electronic Systems GmbH. LMG600 Series Introduction

Thought Technology Ltd Belgrave Avenue, Montreal, QC H4A 2L8 Canada

Introduction. Introductory remarks

Music therapy in mental health care

AABB Trademark Usage Guidelines

SIMATRIX NEO V2 Modular Video Matrix

North West Media Briefing

Cisco Video Surveillance 6400 IP Camera

Act LXXIV of on the rules of broadcasting and digital switchover PART ONE GENERAL PROVISIONS. Chapter I

Kazo Vision. 1. System Chart

Nutrition intervention for optimising physical fitness in children. Mario Vaz St. John s Research Institute Bangalore

INFORMATION AFTERNOON. TUESDAY 16 OCTOBER 4pm to 6pm JAC Lecture Theatre

Product information 19" 1U HD Patch Panel 48xRJ45/s, Cat. 6A, gray, fully populated

Data Mining. Dr. Raed Ibraheem Hamed. University of Human Development, College of Science and Technology Department of CS

Procedures for JDS Section Editors Matt Lucy, EIC Revised 2018

Representing Social Sciences

F5 Network Security for IoT

Mixed Models Lecture Notes By Dr. Hanford page 151 More Statistics& SAS Tutorial at Type 3 Tests of Fixed Effects

Author Guidelines. General Instructions

GK/GN0658. Guidance on Lineside Signal Aspect and Indication Requirements. Rail Industry Guidance Note for GK/RT0058

Colour Control48 Order Code: Control48

For high performance video recording and visual alarm verification solution, TeleEye RX is your right choice!

Some features of children s composing in a computer-based environment. Figure 1. Screenshot of the MelodyMaker application

Dedicated Micros IP v3. Module Application Guide

administration access control A security feature that determines who can edit the configuration settings for a given Transmitter.

Commissioning and Performance of the ATLAS Transition Radiation Tracker with High Energy Collisions at LHC

Advanced Digital Logic Design EECS 303

Transcription:

CDISC Standards Problems and Solutions: Some Examples Paul Terrill and Sarah Brittain

2 Aim To discuss some problems met when creating and processing datasets that follow SDTM (and ADaM) standards.

3 Introduction MDSL International Specialist CRO Supporting Pharma/Biotech companies with limited in-house statistical and data management experience

4 Introduction Overall Problem Clients have limited knowledge about CDISC Not involved from beginning Consequences Difficult to retrospectively follow CDISC Solutions Take on decisions for clients Increased consultancy work Be involved from beginning!

5 Protocol/CRF Design not CDISC Tables and listings to follow protocol/crf SDTM datasets required Problems: 1. CRF not CDASH 2. Trial Dataset Creation

Problem 1: CRF not CDASH 6 Original data (CRF) not collected according to CDASH / controlled terminology Solution Map CRF data to SDTM controlled terminology Back code in ADaM for tables and listings

Problem 1: CRF not CDASH Example 1: Study Termination 7 Study completed according to protocol? If no, indicate one primary reason SDTM (DS domain) - Lack of efficacy - Adverse event - Subject Request - Protocol Deviation - Lost to Follow-up - Death - Other LACK OF EFFICACY ADVERSE EVENT WITHDRAWAL BY SUBJECT PROTOCOL VIOLATION LOST TO FOLLOW-UP DEATH OTHER ADaM (ADDS) LACK OF EFFICACY ADVERSE EVENT SUBJECT REQUEST PROTOCOL DEVIATION LOST TO FOLLOW-UP DEATH OTHER

Problem 1: CRF not CDASH Example 2: Adverse Events 8 Action taken (tick all that apply): - None (1) - Study Drug Discontinued (2) - Study Drug Stop and Restart (3) - Treatment (4) SDTM (1) SUPPAE: QLABEL= Action Taken None QVAL= NONE ADaM (ADAE.AEACT) NONE (2) AE.AEACN= DRUG WITHDRAWN STUDY DRUG DISCONTINUED (3) AE.AEACN= DRUG INTERRUPTED STUDY DRUG STOP AND RESTART (Not 2 or 3) AE.AEACN= DOSE NOT CHANGED (4) AE.AECONTRT= Y TREATMENT

9 Problem 2: Trial Datasets Trial datasets not thought about up front Solutions: Retrospectively produce datasets (time consuming and tricky) Recommend create trial design datasets whilst developing protocols for future projects

Problem 2: Trial Datasets 10 Example 1: Trial Arms Study with open-label period followed by doubleblind period (two treatments) followed by an optional extension study

Problem 2: Trial Datasets 11 Example 1: Trial Arms Create 4 trial arms, although there are only 2 blinded treatments: 1. Open-label Treatment 1 2. Open-label Treatment 1 Extension study 3. Open-label Treatment 2 4. Open-label Treatment 2 Extension study

Problem 2: Trial Datasets 12 ARM CD Example 1: Trial Arms ARM TAET ORD ETCD ELEMENT TABRANCH EPOCH AB TRT1 1 SCREEN SCREENING SCREENING AB TRT1 2 OLTRT OPEN LABEL TRT RANDOMISATION TO TRT1 OPEN-LABEL AB TRT1 3 TRT1 TRT1 DOUBLE-BLIND AB TRT1 4 PT POST-TREATMENT NOT ENTER EXTENSION POST-TREATMENT AB TRT1 5 FU FOLLOW UP FOLLOW UP ABX TRT1-EXT 1 SCREEN SCREENING SCREENING ABX TRT1-EXT 2 OLTRT OPEN LABEL TRT RANDOMISATION TO TRT1 OPEN-LABEL ABX TRT1-EXT 3 TRT1 TRT1 DOUBLE-BLIND ABX TRT1-EXT 4 PT POST-TREATMENT ENTER EXTENSION POST-TREATMENT ABX TRT1-EXT 5 FUX FOLLOW UP EXTENSION AC TRT2 Etc Etc Etc Etc Etc FOLLOW UP

13 Problem 2: Trial Datasets Example 2: Protocol with several Parts Study split into different consecutive parts Part 1: Three period crossover Parts 2 and 3: Placebo controlled, single dose based on dose selection from Part 1 Part 4: Three period crossover

14 Problem 2: Trial Datasets Example 2: Protocol with several Parts Resulting trial design datasets large Use of ARMCD and EPOCH to help distinguish between parts

Problem 2: Trial Datasets Example 2: Protocol with several Parts 15 ARMCD ARM TAET ORD ETCD ELEMENT TABRANCH EPOCH ABC ABC 1 SCREEN SCREENING RANDOMISATION TO TRT ABC SCREENING ABC ABC 2 A TRT A PART 1 FIRST TREATMENT EPOCH ABC ABC 3 B TRT B PART 1 SECOND TREATMENT EPOCH ABC ABC 4 C TRT C PART 1 THIRD TREATMENT EPOCH ABC ABC 5 FU FOLLOW UP FOLLOW UP BAC BAC 1 Etc Etc Etc Etc B B 1 SCREEN SCREENING RANDOMISATION TO TRT B SCREENING B B 2 B TRT B PART 2 AND 3 TREATMENT EPOCH B B 3 FU FOLLOW UP FOLLOW UP A A 1 Etc Etc Etc Etc

16 Processing of Data SDTM datasets repeatedly processed Creation of ADaM Some Listings Efficient methods required Problem: 3. SUPPxx Domains

17 Problem 3: SUPPxx Domains Processing SUPPxx domains Solutions: Use macros that combine SUPP datasets to original domain Create additional database where SUPP dataset variables are included in parent domain (QNAM)

18 Problem 3: SUPPxx Domains Example: Reason for unscheduled visit SUPPSV: RDOMAIN USUBJID IDVAR IDVARVAL QNAM QLABEL QVAL SV 001 VISITNUM 3.1 SVUPREAS Primary Reason for Visit REPEAT LAB TESTS ADSV: Unique Subject Identifier Visit Number Primary Reason for Visit USUBJID VISITNUM SVUPREAS 001 3.1 REPEAT LAB TESTS

19 Non-Standard Data Data collected / CRF does not fit into standard domains SDTM still required Create custom domain or... Put into QS (Questionnaire) type domain

20 Problem 4: Non-Standard Data Example: Subject Diary Drug Accountability Primary source for drug accountability should be CRF but daily Dose taken? Yes/No also collected on a subject diary Solution: Put diary data into QS type domain Use this to derive compliance if necessary

21 Problem 4: Non-Standard Data Example: Subject Diary Drug Accountability QSSEQ QSTESTCD QSTEST QSCAT QSORRES VISITNUM QSDTC QSTPT 1 TRT TRT TAKEN? DRUG YES 2 2010-08-01 DAY 1 2 TRT TRT TAKEN? DRUG YES 2 2010-08-02 DAY 2 3 TRT TRT TAKEN? DRUG NO 2 2010-08-03 DAY 3 4 TRT TRT TAKEN? DRUG YES 2 2010-08-04 DAY 4 5 TRT TRT TAKEN? DRUG YES 2 2010-08-05 DAY 5 Etc Etc Etc Etc Etc Etc Etc Etc

Development Program 22 Consistency Many studies form part of development program Consistency between studies required Problems: 5. TESTCD/PARAMCD 6. Changing Standards

23 Problem 5: TESTCD/PARAMCD Consistency of endpoints and associated xxtestcd / PARAMCD across studies Solutions: Create ongoing master test code list for each program. Use csv format so it can be easily read in to create a format. Try and use the same team within indications / development programs

24 Problem 5: TESTCD/PARAMCD Example: Test codes in a uterine myoma study TESTCD M1VOL M1LOC M1TYP Etc TMVOL ULEN UHGT UDEP UVOL TEST MYOMA 1 VOLUME MYOMA 1 LOCATION MYOMA 1 TYPE Etc TOTAL MYOMA VOLUME UTERUS VOLUME UTERUS HEIGHT UTERUS DEPTH UTERUS VOLUME

25 Problem 6: Changing Standards Changing standards over long-running development programs Solutions: Generally try to use most up to date standard, but... Continually assess backwards compatibility Try to keep the same team working on development programs

Questions 26